Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease
JAMA Network Open · 27.11.2023 · 6 (11) · e2345175
DOI: 10.1001/jamanetworkopen.2023.45175 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 27.11.2023. Verfasst von Cristiano Schaffer Aguzzoli und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Importance Neuropsychiatric symptoms are commonly encountered and are highly debilitating in patients with Alzheimer disease. Understanding their underpinnings has implications for identifying biomarkers and treatment for these symptoms.
Objective
To evaluate whether glial markers are associated with neuropsychiatric symptoms in individuals across the Alzheimer disease continuum. Design, Setting, and Participants This cross-sectional study was conducted from January to June 2023, leveraging data from the Translational Biomarkers in Aging and Dementia cohort at McGill University, Canada. Recruitment was based on referrals of individuals from the community or from outpatient clinics. Exclusion criteria included active substance abuse, major surgery, recent head trauma, safety contraindications for positron emission tomography (PET) or magnetic resonance imaging, being currently enrolled in other studies, and having inadequately treated systemic conditions. Main Outcomes and Measures All individuals underwent assessment for neuropsychiatric symptoms (Neuropsychiatry Inventory Questionnaire [NPI-Q]), and imaging for microglial activation ([ 11 C]PBR28 PET), amyloid-β ([ 18 F]AZD4694 PET), and tau tangles ([ 18 F]MK6240 PET).
Results
Of the 109 participants, 72 (66%) were women and 37 (34%) were men; the median age was 71.8 years (range, 38.0-86.5 years). Overall, 70 had no cognitive impairment and 39 had cognitive impairment (25 mild; 14 Alzheimer disease dementia). Amyloid-β PET positivity was present in 21 cognitively unimpaired individuals (30%) and in 31 cognitively impaired individuals (79%). The NPI-Q severity score was associated with microglial activation in the frontal, temporal, and parietal cortices (β = 7.37; 95% CI, 1.34-13.41; P = .01). A leave-one-out approach revealed that irritability was the NPI-Q domain most closely associated with the presence of brain microglial activation (β = 6.86; 95% CI, 1.77-11.95; P = .008). Furthermore, we found that microglia-associated irritability was associated with study partner burden measured by NPI-Q distress score (β = 5.72; 95% CI, 0.33-11.10; P = .03). Conclusions and Relevance In this cross-sectional study of 109 individuals across the AD continuum, microglial activation was associated with and a potential biomarker of neuropsychiatric symptoms in Alzheimer disease. Moreover, our findings suggest that the combination of amyloid-β– and microglia-targeted therapies could have an impact on relieving these symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
- Brain Institute of Rio Grande do Sul, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
- Global Brain Health Institute, University of California, San Francisco.
- Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services socia…
- Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Förderung
- NIA NIH HHS
Zitieren
APA
Schaffer Aguzzoli, C., Ferreira, P. C. L., Povala, G., Ferrari-Souza, J. P., Bellaver, B., Soares Katz, C., Zalzale, H., Lussier, F. Z., Rohden, F., Abbas, S., Leffa, D. T., Scop Medeiros, M., Therriault, J., Benedet, A. L., Tissot, C., Servaes, S., Rahmouni, N., Cassa Macedo, A., Bezgin, G., …, & Pascoal, T. A. (2023). Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease. JAMA Network Open, 6(11), e2345175. https://doi.org/10.1001/jamanetworkopen.2023.45175
Vancouver
Schaffer Aguzzoli C, Ferreira PCL, Povala G, Ferrari-Souza JP, Bellaver B, Soares Katz C, et al. Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease. JAMA Network Open. 2023;6(11):e2345175. doi:10.1001/jamanetworkopen.2023.45175
BibTeX
@article{SchafferAguzzoli2023,
author = {Schaffer Aguzzoli, Cristiano and Ferreira, Pâmela C L and Povala, Guilherme and Ferrari-Souza, João Pedro and Bellaver, Bruna and Soares Katz, Carolina and Zalzale, Hussein and Lussier, Firoza Z and Rohden, Francieli and Abbas, Sarah and Leffa, Douglas T and Scop Medeiros, Marina and Therriault, Joseph and Benedet, Andréa L and Tissot, Cécile and Servaes, Stijn and Rahmouni, Nesrine and Cassa Macedo, Arthur and Bezgin, Gleb and Kang, Min Su and Stevenson, Jenna and Pallen, Vanessa and Cohen, Ann and Lopez, Oscar L and Tudorascu, Dana L and Klunk, William E and Villemagne, Victor L and Soucy, Jean Paul and Zimmer, Eduardo R and Schilling, Lucas P and Karikari, Thomas K and Ashton, Nicholas J and Zetterberg, Henrik and Blennow, Kaj and Gauthier, Serge and Valcour, Victor and Miller, Bruce L and Rosa-Neto, Pedro and Pascoal, Tharick A},
title = {Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease},
journal = {JAMA Network Open},
year = {2023},
volume = {6},
number = {11},
pages = {e2345175},
doi = {10.1001/jamanetworkopen.2023.45175}
}
EUVIMED